Connect Biopharma Holdings Limited filed a Form 8-K on November 16, 2026, disclosing that it received a Nasdaq deficiency notice on November 12, 2026, for failing to maintain the minimum $1.00 bid price requirement, and separately reporting its financial results for the three and nine months ended September 30, 2026.
Key Highlights
- Deficiency notice received: On November 12, 2026, Connect Biopharma received a letter from Nasdaq's Listing Qualifications Department indicating its ordinary shares had closed below $1.00 per share for the last thirty consecutive business days.
- Listing rule cited: The notice references Nasdaq Listing Rule 5450(a)(1), the Minimum Bid Price Requirement for continued listing on the Nasdaq Global Market.
- Compliance deadline: The company has 180 calendar days, until May 11, 2027, to regain compliance with the Minimum Bid Price Requirement.
- Compliance threshold: Nasdaq will confirm compliance if the closing bid price is at least $1.00 for a minimum of ten consecutive business days, subject to Nasdaq's discretion to require up to 20 consecutive business days.
- No immediate trading impact: According to the filing, the Nasdaq letter "has no immediate effect on the listing or trading of the Company's ordinary shares," which continue to trade under the symbol NASDAQ:CNTB.
- Potential additional period: If compliance is not regained by May 11, 2027, the company may be eligible for an additional 180 calendar day compliance period, contingent on factors including a potential transfer to the Nasdaq Capital Market.
- Financial results also reported: The company simultaneously furnished a press release covering financial results for the three and nine months ended September 30, 2026, attached as Exhibit 99.1.
Connect Biopharma Discloses Nasdaq Minimum Bid Price Deficiency and Q3 2026 Results
According to the Form 8-K filed November 16, 2026, Connect Biopharma Holdings Limited (NASDAQ:CNTB) disclosed that on November 12, 2026, it received a written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC. The notice stated that the company's ordinary shares had closed below the minimum $1.00 per share bid price for the last thirty consecutive business days, triggering a deficiency under Nasdaq Listing Rule 5450(a)(1).
The filing states that, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the company has been granted an initial 180-calendar-day period ending May 11, 2027, to regain compliance. Compliance would be confirmed in writing by Nasdaq staff if the closing bid price reaches at least $1.00 for a minimum of ten consecutive business days, though the filing notes Nasdaq retains discretion to require up to 20 consecutive business days. The company disclosed it "intends to monitor the bid price of its ordinary shares and to consider available options" if its shares do not trade at a level likely to result in regaining compliance by the deadline.
The filing also notes that if the company fails to regain compliance by May 11, 2027, it may be eligible for an additional 180-calendar-day period, subject to conditions including successfully transferring its listing to the Nasdaq Capital Market and meeting other Nasdaq listing requirements. Separately, under Item 2.02, the company furnished a press release dated November 16, 2026, as Exhibit 99.1, reporting financial results for the three and nine months ended September 30, 2026. The filing specifies that the Item 2.02 information is furnished, not filed, and is not subject to Section 18 liabilities of the Securities Exchange Act of 1934.
What Was Disclosed
Connect Biopharma Holdings Limited reported receiving a Nasdaq bid price deficiency notice on November 12, 2026, with a compliance deadline of May 11, 2027, and no immediate effect on trading. The company also furnished its Q3 2026 financial results via press release.




Please wait processing your request...